Table of Contents
“If your telehealth business is technically compliant today, are you sure it will still be compliant after your next product launch, pharmacy partnership, or marketing campaign?”
That’s the uncomfortable question healthcare operators need to be asking right now.
The rules around telehealth and pharmacy operations aren’t sitting still. And in 2026, regulators are looking much more closely at what happens around the prescription, not just the prescription itself.
For GLP-1 businesses especially, the scrutiny has been pretty hard to miss.
The FDA issued warning letters to 30 telehealth companies in March 2026 over misleading claims involving compounded GLP-1 products. The agency specifically called out claims suggesting compounded drugs were the same as FDA-approved products, as well as marketing that obscured who actually compounded the medication.
Then, in April, the FDA clarified its expectations around compounding GLP-1 drugs under the federal 503A and 503B frameworks as the national supply situation changed.
So if you’re operating a telehealth pharmacy business, or supporting one, compliance isn’t something to check once a year.
It’s becoming part of day-to-day operations.
1. FDA Is Paying Much More Attention to How Compounded Drugs Are Marketed
This is probably the biggest development GLP-1 brands should have on their radar.
The FDA has been very clear that compounded drugs are not FDA-approved. They aren’t reviewed by the agency for safety, effectiveness, or quality before being marketed in the same way FDA-approved drugs are.
That means wording matters.
A lot.
A telehealth company shouldn’t casually describe a compounded medication as the “same” as an FDA-approved drug, call it a generic version, or imply that the compounded product itself has been FDA-approved.
The FDA has also warned against branding that makes it look as though the telehealth company itself is the compounder when it isn’t.
For operators, this means compliance isn’t just sitting with the clinical or legal team.
Marketing needs to be part of the conversation too.
A landing page can create a compliance problem just as easily as a prescribing workflow can.
2. Compounding Rules Around GLP-1s Have Become More Specific
The FDA’s April 2026 clarification is particularly relevant for businesses working with compounded semaglutide and similar products.
Under section 503A, for example, a compounded drug generally needs to be made for an individual patient based on a prescription, and there are restrictions around regularly or excessively compounding products that are essentially copies of commercially available drugs. There are specific considerations around whether a prescriber documents a significant difference for an individual patient.
That’s a lot more nuanced than:
“We have a prescription, so we’re good.”
And that’s exactly why telehealth companies need their pharmacy and compliance teams talking to each other.
The prescription workflow, pharmacy relationship, product being dispensed, and marketing language can’t be treated as completely separate things.
3. The Controlled-Substance Telehealth Rules Are Still Moving
Here’s another one worth watching.
HHS and DEA extended the current federal telemedicine flexibilities for prescribing controlled substances through December 31, 2026. Under the temporary framework, eligible DEA-registered practitioners can prescribe Schedule II-V controlled substances via telemedicine without a prior in-person evaluation, provided the applicable conditions are met. (hhs.gov)
But there’s more happening behind the scenes.
On August 25, 2026, the DEA submitted a proposed final framework for special registration for telemedicine prescribing to OMB for review. The actual final rule text wasn’t publicly available in the report I found, so this should be treated as a development to monitor, not as a new rule already in effect. (healthcareitnews.com)
For telehealth operators, the practical takeaway is pretty simple:
Don’t build your long-term compliance strategy around a temporary rule.
Keep watching the federal framework and the laws in every state where your patients are located.
4. Pharmacy Fulfillment Is Becoming Part of the Compliance Conversation
It’s easy to think of compliance as something that happens when the provider writes the prescription.
It doesn’t.
What happens afterward matters too.
Who receives the prescription?
Is the pharmacy appropriately licensed?
Is the prescription routed correctly?
Can your team identify where an order is sitting?
Are patients receiving accurate information?
What happens when the pharmacy needs clarification?
For GLP-1s, the FDA has specifically warned about issues including fraudulent pharmacy information, improper storage during shipping, and dosing errors associated with some compounded products. As of May 31, 2026, the FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
That puts fulfillment firmly on the operational radar.
A prescription that leaves the provider’s system isn’t necessarily the end of your responsibility as a telehealth business.
5. State Rules Still Matter
One of the easiest mistakes for a growing telehealth company is thinking federal compliance is the whole picture.
It isn’t.
State requirements can differ around telehealth, provider licensing, prescribing, pharmacy operations, and controlled substances.
And those rules can change independently.
For example, North Carolina’s medical board recently reiterated that the federal controlled-substance telemedicine flexibility currently runs through December 31, 2026, while also reminding providers that all other applicable federal and state requirements still apply. (ncmedboard.org)
So if you’re expanding from five states to twenty, your compliance workload isn’t simply multiplying by four.
Your operating model is changing.
What Should Telehealth Brands Be Watching?
If I were running a telehealth business right now, I’d have this short list sitting somewhere visible:
☐ Review claims made about compounded medications
☐ Make it clear who actually compounds and dispenses the medication
☐ Review GLP-1 marketing and product descriptions
☐ Keep pharmacy licenses and relationships current
☐ Monitor federal compounding developments
☐ Track DEA telemedicine rule changes
☐ Review state-specific prescribing requirements
☐ Check how prescriptions and fulfillment information move between systems
☐ Make sure patients receive accurate medication and fulfillment information
☐ Have a process for handling pharmacy or medication-related exceptions
The point isn’t to panic every time the FDA publishes something.
It’s to stop treating compliance as a document sitting in a folder.
What Does This Mean for Telehealth Pharmacy Operations?
The direction is pretty clear.
Regulators are looking more closely at the entire medication journey.
That means healthcare brands need better visibility into what happens from consultation → prescription → pharmacy → fulfillment → patient.
This is where infrastructure matters.
RxAve helps telehealth businesses connect prescription routing, pharmacy coordination, fulfillment workflows, refill management, and operational visibility, giving teams a clearer view of what’s happening after the provider writes the prescription.
Because when regulations change, having disconnected systems makes adapting harder.
A connected operation gives your team somewhere to start.
FAQs
What are the latest pharmacy and telehealth compliance requirements in 2026?
There isn’t one new rule that covers everything. Right now, brands should be watching FDA requirements around compounded drugs, federal telemedicine prescribing rules, state-specific requirements, pharmacy regulations, and privacy obligations. The details depend heavily on the medications and states involved.
How do telehealth regulations affect pharmacy fulfillment?
They can affect who is allowed to prescribe, where providers can practice, how prescriptions are routed, which pharmacies can dispense them, and what documentation is required. So fulfillment can’t really be separated from the broader telehealth compliance picture.
What compliance issues should telehealth brands monitor in 2026?
Keep an eye on compounded-drug marketing, provider licensing, patient location, pharmacy relationships, prescribing rules, medication handling, patient communications, and state law changes. For GLP-1 brands, FDA scrutiny of compounded products deserves particular attention. (fda.gov)
Are compounded medications allowed through telehealth platforms?
Sometimes, but there isn’t a blanket, yes. Federal compounding requirements, the specific medication, the patient’s clinical need, the pharmacy or outsourcing facility, and state requirements can all matter. Compounded drugs are not FDA-approved, and telehealth companies shouldn’t assume that every compounded product can be marketed or dispensed in the same way.
How can telehealth companies stay compliant with changing pharmacy regulations?
Don’t wait for a regulation to become a crisis. Keep legal and clinical teams involved, review pharmacy relationships regularly, monitor federal and state updates, and make sure your operational systems can adapt when requirements change. In a market moving this quickly, compliance needs to be an ongoing process, not an annual checkbox.